🔮 OOTWOracle · Live odds · All predictions · Track record

🔮 Today's Oracle Signal — August 5, 2026

No FDA advisory-committee or Type B meeting is publicly scheduled for TRP-8803 within 12 weeks; the '72-patient commercialisation' claim gets corrected to a designation.

68% confidence Clinical · Resolves 2026-10-28

→ Read full August 5, 2026 Oracle report

Which Psychedelic Company Is Closest to FDA Approval?

A tracked, falsifiable answer from OOTWOracle · updated August 5, 2026

No psychedelic company has an FDA-approved product yet. As of August 5, 2026, MDMA-assisted therapy for PTSD (Lykos Therapeutics) advanced furthest into the process but received an FDA complete response letter requiring another Phase 3 trial, resetting its timeline. COMPASS Pathways' psilocybin program (COMP360) is the furthest-along active Phase 3 effort, in treatment-resistant depression. So the honest answer is: closest in the regulatory process is MDMA (but delayed); closest with active late-stage trials running is COMPASS. The Oracle currently puts it at 80% that veterans' mushroom study won't trigger any FDA review meetings this year (resolves 2026-09-30).

Several companies are racing toward the first FDA-approved psychedelic medicine, but 'closest' depends on how you count: furthest through the regulatory process, or furthest with trials actively running. Both answers matter, and neither has crossed the finish line. Here is the grounded picture, with the Oracle's dated odds attached.

Current odds on this question

Oracle odds	Prediction (falsifiable)	Resolves
80%	Veterans' mushroom study won't trigger any FDA review meetings this year	2026-09-30
76%	Veterans' psilocybin study will inspire advocates but won't move regulators in 2026	2026-10-29
72%	Ibogaine heart-risk rules block any new ketamine-addiction trial starting	2026-10-27
72%	Veteran psilocybin study gets political buzz but no FDA response	2026-10-10
70%	COMPASS Pathways' psilocybin drug program hits no major US regulatory milestone	2026-10-13

Every row is a public, dated, falsifiable prediction — scored against a written resolution rule when the date arrives. Methodology & hit-rate: the track record.

Frequently asked

Has any psychedelic been FDA-approved?

No. As of August 5, 2026, no psilocybin or MDMA product has FDA marketing approval; both remain Schedule I federally.

Is Lykos (MDMA) or COMPASS (psilocybin) closer?

Lykos went furthest in the formal review but was sent back for another Phase 3, which delayed it. COMPASS has the furthest-along active Phase 3 program. 'Closest' depends on which you weight.

Could the first approval come in 2026?

The Oracle's odds favor no full FDA approval of a psychedelic in 2026; the nearest realistic path is a tightly-controlled approval later, after additional confirmatory data.

What about smaller players like atai or MindMed?

They have programs in earlier or mid-stage development. Being in trials is not the same as nearing approval — watch for Phase 3 readouts and accepted New Drug Applications, not press language.

Related answers: Will psilocybin be approved? · Will MDMA be approved? · Full odds sheet